市場調查報告書
商品編碼
965024

羥基氯金藥物市場的增長,趨勢和預測(2020-2025)

Hydroxychloroquine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

預測期內,羥氯奎藥物的全球市場預計將以約16.8%的複合年增長率增長。羥氯金是氯金的安全衍生物。羥氯奎是一種免疫抑制和抗寄生蟲藥,可用於治療或預防瘧疾,但該藥對耐氯黴素的瘧疾無效。還推薦使用羥氯奎治療自身免疫性疾病,例如全身性和盤狀紅斑以及類風濕性關節炎(急性和重度),而其他藥物無法使用或無法使用。廣譜羥氯激□藥物可用於治療多種病毒。根據中國科學技術部的說法,羥氯奎是在早期臨床試驗中顯示出有前景的阻斷冠狀病毒的藥物之一。

最近,羥氯奎已經引起了人們的注意,因為它可以有效治療冠狀病毒(COVID-19)患者。來自中國的一份報告表明,氯奎可能在體外抑制SARS-CoV-2。已建議該藥物在治療冠狀病毒患者中非常有效。羥氯奎有望成為冠狀病毒的有前途的潛在治療方法。美國食品和藥物管理局(FDA)已指定將羥氯奎緊急用於治療冠狀病毒(COVID19)。

市場對新羥氯奎的需求不斷增長,仿製藥的滲透率預計將顯著增長。例如,諾華國際公司(Novartis International AG)和美國衛生與社會福利部(HHS)於2020年3月進行了一項對照臨床試驗,以評估羥氯奎對冠狀病毒檢測呈陽性的人群的療效。已經開始出貨3000萬次羥氯奎片劑。此外,隨著政府資金的增加,更多的產品批准有望更深入地滲透市場。

隨著患者對COVID-19意識的增強以及新仿製藥在全球範圍內的湧入,有望加速羥氯奎藥物的採用。根據約翰霍普金斯大學的數據,截至2020年4月15日,僅在美國就有609,516人患有COVID-19。估計人們對疾病治療的認識不斷提高,以及評估羥基氯奎在治療COVID-19中的療效的臨床試驗越來越多,預計將增加利潤。但是,低收入國家缺乏醫療保健機會可以抑制市場增長。

本報告調查了羥氯奎藥物市場,並提供了市場概況,以及按應用,分銷渠道,地區和進入市場的公司概況的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場驅動力
    • 冠狀病毒等疾病的暴發(COVID 19)
    • 瘧疾和類風濕關節炎高發
    • 增加產品發佈和批准
    • 在各種治療條件下擴大對羥基氯奎的使用
  • 市場限制因素
    • 世界範圍內缺乏羥氯金
    • 低收入國家/地區的醫療保健條件差
  • 波特的五力分析

第5章市場細分

  • 按應用
    • 新型冠狀病毒(COVID-19)
    • 瘧疾
    • 紅斑狼瘡
    • 類風濕關節炎
  • 按分銷渠道
    • 在線藥房
    • 醫院內藥房
    • 零售藥房
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東/非洲
    • 南美洲

第6章競爭情況

  • 公司簡介
    • DR. REDDY'S LABORATORIES LTD
    • Laurus Labs Limited,
    • Lupin
    • Mylan NV
    • Novartis International AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceuticals USA Inc.
    • Zydus Pharmaceuticals

第7章市場機會和未來趨勢

目錄
Product Code: 69353

The global hydroxychloroquine drugs market studied was anticipated to register a CAGR of nearly 16.8% during the forecast period. Hydroxychloroquine is a safer derivative of chloroquine. Hydroxychloroquine is an immunosuppressive and anti-parasite drug indicated for the treatment or prevention of malaria, although the drug is ineffective for chloroquine-resistant malaria. Hydroxychloroquine is also recommended for autoimmune diseases such as systemic and discoid lupus erythematosus, and rheumatoid arthritis (acute and severe) when other medications fail to work or cannot be used. Broad-spectrum hydroxychloroquine drugs can be used to treat a range of viruses. According to China's Ministry of Science and Technology, hydroxychloroquine is one of the drugs which demonstrated encouraging profile for blocking coronavirus in early clinical trials.

Recently, hydroxychloroquine has attracted attention due to its effectiveness in treating patients with coronavirus disease (COVID 19). Reports from China demonstrated chloroquine could possibly inhibit SARS-CoV-2 in vitro. The drug showed high efficacy in treating the patients with coronavirus disease (COVID 19). Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19).

Increasing demand for novel hydroxychloroquine and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in March 2020, Novartis International AG started the shipping of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19). In addition, increasing product approval is poised to have strong market penetration due to the presence of increased government funding.

Growing patient awareness regarding COVID-19 and the influx of new generics in the global arena are projected to accelerate the adoption of hydroxychloroquine drugs. As per the Johns Hopkins University, as of 15th April 2020, approximately 609,516 people suffered from COVID-19 in the US alone. Increasing awareness regarding disease remittance therapies, rising clinical trials to evaluate the effectiveness of hydroxychloroquine in the treatment of COVID-19 are estimated to promote revenue growth. However, poor healthcare accessibility in low-income countries may restrain the growth of the market.

Key Market Trends

Rheumatoid Arthritis Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

  • Rheumatoid arthritis is expected to dominate the global hydroxychloroquine drugs market through the forecast period. This can be attributed to the rising prevalence of rheumatoid arthritis, which causes different symptoms, such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and the risk of joint replacement.
  • According to the World Health Organization, more than 23 million people live with rheumatoid arthritis. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and low price of generic drugs for the target disease are supplementing the growth of the segment.
  • Moreover, COVID-19 is estimated to be the fastest-growing segment over the forecast period. Exponentially increasing cases worldwide is the major factor expected to drive the vertical over the forecast period. The World Health Organization declared coronavirus disease (COVID 19) as a pandemic on March 11, 2020. As per the Johns Hopkins University, till the date April 15, COVID-19 is responsible for more than 126,859 deaths worldwide. Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19). All the aforementioned factors expected to bode a well for this vertical.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA and COVID-19, and high public and private healthcare spending are stimulating the growth of the region. Moreover, the World Health Organization estimates that by the end of 2040, 54.4 million adults in the country may suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

Asia-Pacific is likely to post the fastest market throughout the forecast horizon. Lack of disease awareness in some underdeveloped regions is leading to an expanding base of patients in the region. This, coupled with increasing healthcare spending, presence of key manufacturers, such as Zydus Cadila, Novartis, and Sun Pharmaceuticals, and growing product approvals, is expected to propel the market in APAC. Increasing demand for target drug for disease reversal is poised to augment the regional markets during the forecast period.

Competitive Landscape

Manufacturers offering generic versions dominate the global hydroxychloroquine drugs market. Companies are focusing on building generic chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are DR. REDDY'S LABORATORIES LTD, Laurus Labs Limited, Lupin, Mylan NV, Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals.

The introduction of generic versions and the strong clinical pipeline is anticipated to increase competition in the market. For instance, in April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability with the aim to increase production capacity by 5-6 times to 70 MT per month thereby, expanding the range of treatment options for the millions of patients living with target diseases.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Disease Outbreaks Such As Coronavirus Disease (COVID 19)
    • 4.2.2 High prevalence of Malaria and Rheumatoid Arthritis
    • 4.2.3 Increasing Product Launches and Approvals
    • 4.2.4 Expanding Application of Hydroxychloroquine in Various Therapeutic Conditions
  • 4.3 Market Restraints
    • 4.3.1 Global Shortage of Hydroxychloroquine
    • 4.3.2 Poor Healthcare Accessibility in Low Income Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Coronavirus Disease (COVID-19)
    • 5.1.2 Malaria
    • 5.1.3 Lupus Erythematosus
    • 5.1.4 Rheumatoid Arthritis
  • 5.2 By distribution Channel
    • 5.2.1 Online Pharmacy
    • 5.2.2 Hospital Pharmacy
    • 5.2.3 Retail Pharmacy
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 DR. REDDY'S LABORATORIES LTD
    • 6.1.2 Laurus Labs Limited,
    • 6.1.3 Lupin
    • 6.1.4 Mylan NV
    • 6.1.5 Novartis International AG
    • 6.1.6 Sanofi SA
    • 6.1.7 Sun Pharmaceutical Industries Ltd
    • 6.1.8 Teva Pharmaceuticals USA Inc.
    • 6.1.9 Zydus Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS